Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL383731 | 0.98 | TSHR (0.32) | TSHRNLRP3 | |
| SCHEMBL566248 | 0.91 | TSHR (0.31) | TSHR | |
| SCHEMBL10030503 | 0.91 | TSHR (0.35) | TSHR | |
| SCHEMBL14136628 | 0.90 | TSHR (0.30) | TSHRNLRP3 | |
| SCHEMBL2621446 | 0.90 | TSHR (0.30) | TSHRNLRP3 | |
| SCHEMBL16504168 | 0.90 | TSHR (0.30) | TSHRNLRP3 | |
| SCHEMBL17133199 | 0.89 | — | — | |
| SCHEMBL18541723 | 0.89 | — | — | |
| SCHEMBL22743730 | 0.89 | NLRP3 (0.31) | NLRP3 | |
| SCHEMBL2397817 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7427675-B2 | Compounds and methods for the characterization of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-7427675-B2 | Compounds and methods for the characterization of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| WO-2006023880-A2 | COMPOUNDS AND METHODS FOR THE CHARACTERIZATION OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20060040308-A1 | Compounds and methods for the characterization of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040308-A1 | Compounds and methods for the characterization of oligonucleotides | POLRMT, DCLRE1B, RNGTT | TSHR 2682/4885NLRP3 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.